NCT03128411COMPLETEDanonymous

A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF BOSUTINIB MONOTHERAPY IN JAPANESE ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA

Sponsor

Source record

Pfizer

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

Bosutinib

Indication / condition

AI-normalized

Leukemia, Chronic Myelogenous

Intervention

Source record

Bosutinib

Related intelligence directories

Indication directory: Leukemia Modality directory: small molecule Target directory: Bosutinib

Source & freshness

Source record

NCT ID

NCT03128411

Original source

ClinicalTrials.gov

Source last updated

May 19, 2022

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT03128411

Title

A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF BOSUTINIB MONOTHERAPY IN JAPANESE ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA

Sponsor

Pfizer

Status

COMPLETED

Phase

PHASE2

Condition raw

Leukemia, Chronic Myelogenous

Condition normalized

Leukemia, Chronic Myelogenous

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Bosutinib

Target normalized

Bosutinib

Interventions

Bosutinib

Public preview

Source record

Phase 2, single-arm, open-label trial. Patients will receive bosutinib for the duration of the study.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF BOSUTINIB MONOTHERAPY IN JAPANESE ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT03128411

Status

COMPLETED

Phase

PHASE2

Sponsor

Pfizer

Executive brief

Investment-Ready Snapshot

Phase 2, single-arm, open-label trial. Patients will receive bosutinib for the duration of the study.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedMay 19, 2022

Internal syncJun 11, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03128411

Indication

Leukemia, Chronic Myelogenous

Modality

small molecule

Target

Bosutinib

Intervention

Bosutinib

Source record